Erez Israeli
CanadaexecutiveMale5.0Global Dominance: 0.00%Erez Israeli is the Chief Executive Officer of Dr. Reddy’s Laboratories Ltd., an Indian multinational pharmaceutical company. Under his leadership, the company has focused on expanding its generic drug portfolio, including efforts to introduce generic versions of key therapies like semaglutide in major markets. Recently, he addressed the company's plans and challenges regarding regulatory approvals for semaglutide, a popular diabetes and weight-loss medication.
Country presence
Recent news mentions
Erez Israeli, Dr. Reddy’s chief executive officer, disclosed issues at a facility upgrading to produce semaglutide.
Apotex emerges as only supplier of generic Ozempic in Canada for nowCanada· 2026-07-29
Erez Israeli is the CEO of Dr. Reddy’s, which plans to launch the generic version of semaglutide in 87 countries.
Is India about to make Ozempic-like weight-loss drugs a whole lot cheaper?
United States· 2026-02-08
Erez Israeli, the drugmaker’s chief executive officer, said on an earnings call on July 23 that the company was prioritizing a launch in Canada.
Indian pharma giant says Health Canada rejected its application to make generic semaglutideCanada· 2025-10-30
